The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics Lawsuit - MGNX

Core Viewpoint - MacroGenics, Inc. (NASDAQ: MGNX) faces a class action lawsuit due to alleged misrepresentations regarding the safety data of its drug vobramitamab duocarmazine during the TAMARACK Phase 2 study, leading to a significant stock decline of 77.4% [1][2]. Group 1 - The class period for the alleged misrepresentations is from March 7, 2024, to May 9, 2024 [1]. - On May 9, 2024, it was revealed that the drug was significantly more dangerous than previously stated, resulting in a stock price drop of $11.36 per share [1]. - The Gross Law Firm is encouraging shareholders who purchased MGNX shares during the class period to register for potential lead plaintiff appointment [2]. Group 2 - The deadline for shareholders to register for the class action is September 24, 2024 [2]. - Registered shareholders will receive updates through portfolio monitoring software throughout the case lifecycle [2]. - There is no cost or obligation for shareholders to participate in the case [2]. Group 3 - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements or omissions by companies [3]. - The firm emphasizes the importance of responsible business practices and corporate citizenship [3]. - The firm is recognized nationally for its class action lawsuits [3].